NeoImmuneTech, Inc.

76 articles about NeoImmuneTech, Inc.

• NeoImmuneTech's NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting

  4/9/2024

  NeoImmuneTech, Inc. today presented a poster on a pre-clinical study that opens a new field of potential applications for NT-I7 (efineptakin alfa).

• NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

  4/2/2024

  NeoImmuneTech, Inc., announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer of NeoImmuneTech, Inc., effective from March 29, 2024.

• FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7 for Advanced Pancreatic Cancer Treatment

  1/30/2024

  NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted NT-I7 (efineptakin alfa) (rhIL-7-hyFc) Orphan Drug Designation (ODD) for the treatment of pancreatic cancer.

• NeoImmuneTech Welcomes a New President for its Development and Business

  1/15/2024

  NeoImmuneTech, Inc. announces the appointment of Luke Oh, Ph.D., as President, effective immediately.

• NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments

  12/11/2023

  Imugene Ltd and NeoImmuneTech, Inc. announced a strategic collaboration to evaluate Imugene's allogeneic CAR T, azer-cel, in combination with NIT's proprietary immune T cell amplifier "Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.

• FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome

  11/20/2023

  NeoImmuneTech, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for their investigational drug NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of Acute Radiation Syndrome (ARS).

• NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board

  7/26/2023

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announces the addition of two distinguished experts to its Scientific Advisory Board.

• NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)

  1/3/2023

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced an agreement with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, to develop NeoImmuneTech's main asset NT-I7, for the treatment of Acute Radiation Syndrome.

• New evidence of NeoImmuneTech's NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors

  11/11/2022

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, presented new data from its phase 2a clinical study NIT-110, at the Society for Immunotherapy of Cancer 2022 annual meeting.

• NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting

  11/4/2022

  NeoImmuneTech, Inc. announced it will present first data from the combination of its main asset, NT-I7, with the chimeric antigen receptor T-cell tisagenlecleucel, at the American Society of Hematology annual meeting, to be held in New Orleans, Louisiana, December 10-13, 2022.

• NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting

  10/5/2022

  NeoImmuneTech, Inc. today announced it will present development progress of its main asset, NT-I7 (efineptakin alfa), across five presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston , November 8, 2022.

• NeoImmuneTech's NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab

  9/12/2022

  NeoImmuneTech, Inc., a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells in cold tumors, at the European Society for Medical Oncology Congress in Paris, France, September 9-13, 2022.

• NeoImmuneTech Welcomes New Members to its Scientific Advisory Board

  8/8/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of new members of its Scientific Advisory Board.

• FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7 for the treatment of Glioblastoma Multiforme

  7/13/2022

  NeoImmuneTech, Inc., a T cell-focused therapeutics company, announced that the U.S. Food and Drug Administration has granted NT-I7 Orphan Drug Designation for the treatment of Glioblastoma Multiforme.

• A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

  6/14/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused therapeutics company, reported that Nature Communications (Impact Factor: 14.92) published the results of an in vivo study combining the long-acting human IL-7, NT-I7, with chimeric antigen receptor (CAR) T cells directed against CD19+ B cell lymphoma and acute myeloid leukemia.

• NeoImmuneTech to Present at Upcoming BIO International Convention

  6/13/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang , Ph.D., MBA, will present a company update at the upcoming BIO International Convention, to be held June 13-16 in San Diego, CA.

• NeoImmuneTech's Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

  6/6/2022

  NT-I7 plus pembrolizumab showed anti-tumor activity in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective.

• NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting

  4/27/2022

  NeoImmuneTech, Inc. today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022.

• NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022

  4/13/2022

  Pre-clinical studies demonstrate NT-I7’s potential to enhance anti-tumor responses in combination with compounds targeting multiple biological pathways.

• 

  Money on the Move: March 9-15

  3/16/2022

  The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates.